Advanced Biomed financials
$6.32−6.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$519.8K | -$396.6K | -$523.9K | -$1.2M | -$567.5K |
| Net income | -$488.9K | $6.9M | -$386.9K | -$701.6K | -$1.4M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.38 | $6.20 | $-0.40 | $-0.34 | $-1.35 |
| EBITDA | -$510.5K | -$409.5K | -$475.9K | -$1.1M | -$545.0K |
| Operating cash flow | -$239.8K | -$513.6K | -$610.3K | -$1.5M | -$3.4M |
| Free cash flow | -$241.0K | -$526.5K | -$612.1K | -$1.6M | -$3.4M |
| Diluted shares | 1.3M | 1.1M | 1.1M | 2.1M | 1.0M |
Balance sheet
| Period end | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $2.6M | $2.6M | $2.7M | $2.9M | $5.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $10.6M | $10.9M | $6.2M | $13.7M | $8.3M |
| Total liabilities | $1.4M | $1.4M | $3.2M | $10.2M | $4.2M |
| Shareholders' equity | $9.2M | $9.5M | $3.0M | $3.5M | $4.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology